Default company panoramic image

Nemucore Medical Innovations

Raising Funds to Initiate Phase I Clinical Trials in Ovarian Cancer Leveraging $4.3 million in Non-dilutive Financing.

  • Stage Concept Only
  • Industry Biotechnology
  • Location Worcester, MA, USA
  • Currency USD
  • Website

Company Summary

Nemucore Medical Innovations, Inc. is a biopharmaceutical company dedicated to the development and commercialization of life-saving nanomedicines for the treatment of multi-drug resistant cancers, particularly ovarian cancer. Our clinical candidates, NMI-300 a treatment for platinum-resistant cancer & NMI-500 a treatment for taxane-resistant cancer are expected to enter clinical trials in 18-24 months.


  • Default avatar
    Timothy P. Coleman
    CEO and President

    Tim is co-founder and a serial entrepreneur who has successfully founded and built several companies from early stage funding through strategic expansion over a 20 year career. Tim worked with PwCs healthcare advisory practice as a manager where he still assists the practice as a senior life science fellow. Tim has an MBA from the Boston University School of Management and a PhD in molecular biophysics from the Medical College of Virginia at VCU

  • Default avatar
    P. Michael Masterson
    Executive Chairman

    Mr. Masterson is a co-founder and an accomplished engineer, business executive, entrepreneur, and investor with experience in commercializing healthcare technologies and in building healthcare businesses. He earned chemical engineering degrees (BS and MS) from the University of Massachusetts and the University of Colorado and is a graduate of the Owners-President Management program at the Harvard Business School.

  • Default avatar
    Susan Riley Keyes
    Vice President

    Prior to joining Nemucore, Dr. Keyes acted as the Associate Director and Technology Transfer Executive at Northeastern University. Dr. Keyes was responsible for marketing and licensing its intellectual property. She managed all aspects of commercialization for life science technologies. Prior to Northeastern, Dr. Keyes held positions at Yale, Dana-Farber Cancer Institute, and Ipsen Pharmaceuticals/ Biomeasure, focusing primarily in oncology.

  • Default avatar
    Michael Briggs
    Interim Chief Scientific Officer

    Dr. Briggs has been in the pharmaceutical industry for the past 18 years including work in cardiovascular and metabolic disease and functional genomics. Most recently he was the Senior Director of Biology at Vertex Pharmaceuticals. Recently he led research teams in the US and China to develop primary human cancer tumor models. These models have elucidated aspects of drug discovery including new approaches to effective drug combination therapies.